Literature DB >> 29523991

Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.

Dan Călugăru1, Mihai Călugăru2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29523991     DOI： 10.1007/s00417-018-3951-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  10 in total

1.  Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.

Authors:  Rita Laiginhas; Marta Inês Silva; Vitor Rosas; Susana Penas; Vitor Adriano Fernandes; Amândio Rocha-Sousa; Ângela Carneiro; Fernando Falcão-Reis; Manuel Sousa Falcão
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-10-29       Impact factor: 3.117

Review 2.  TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.

Authors:  K Bailey Freund; Jean-François Korobelnik; Robert Devenyi; Carsten Framme; John Galic; Edward Herbert; Hans Hoerauf; Paolo Lanzetta; Stephan Michels; Paul Mitchell; Jordi Monés; Carl Regillo; Ramin Tadayoni; James Talks; Sebastian Wolf
Journal:  Retina       Date:  2015-08       Impact factor: 4.256

3.  Letter to the Editor: Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2017-04-01       Impact factor: 1.300

4.  Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-07       Impact factor: 3.117

5.  Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2016-11-25       Impact factor: 5.258

6.  Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  J Ocul Pharmacol Ther       Date:  2014-10-14       Impact factor: 2.671

7.  Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2016-06-04       Impact factor: 5.258

8.  Letter to the Editor: Aflibercept For Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab And/Or Bevacizumab May Further Improve Macular Thickness.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2017-07-01       Impact factor: 1.300

9.  Early Response to Intravitreal Dexamethasone Implant Therapy in Diabetic Macular Edema May Predict Visual Outcome.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2017-12-06       Impact factor: 5.258

10.  Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis).

Authors:  Sandeep Grover; Ravi K Murthy; Vikram S Brar; Kakarla V Chalam
Journal:  Am J Ophthalmol       Date:  2009-05-09       Impact factor: 5.258
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.